Nuvectis Pharma, Inc.
NVCT
$18.96
-$0.27-1.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.67% | -14.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.97% | -17.82% | |||
| Operating Income | -14.97% | 17.82% | |||
| Income Before Tax | -16.03% | 17.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.03% | 17.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.03% | 17.28% | |||
| EBIT | -14.97% | 17.82% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -15.71% | 18.05% | |||
| Normalized Basic EPS | -15.73% | 18.06% | |||
| EPS Diluted | -15.71% | 18.05% | |||
| Normalized Diluted EPS | -15.73% | 18.06% | |||
| Average Basic Shares Outstanding | 0.26% | 0.94% | |||
| Average Diluted Shares Outstanding | 0.26% | 0.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||